Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?

Biol Blood Marrow Transplant. 2020 Sep;26(9):e237-e238. doi: 10.1016/j.bbmt.2020.05.003. Epub 2020 May 16.

Authors

Selin Kucukyurt¹, Tugrul Elverdi¹, Ahmet Emre Eskazan²

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
² Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Electronic address: emre.eskazan@istanbul.edu.tr.

PMID: 32428733
DOI: 10.1016/j.bbmt.2020.05.003

No abstract available

Publication types

Letter
Comment

MeSH terms

Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / therapy
Lymphocytes
Protein Kinase Inhibitors
Recurrence

Substances

Protein Kinase Inhibitors